Key facts
- RejuvenAir’s last known valuation is $156.0M.
- It has raised $191.4M; the latest was Later Stage VC ($59.7M) in Sep 2024.
- Notable investors include Innovate UK, TEDCO, SV Health Investors, Ascension Ventures, Rose Park Advisors — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for RejuvenAir
- ·The full record, as it builds
Funding rounds
No funding rounds for RejuvenAir are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About RejuvenAir
Developer of an interventional device designed to offer the therapy of chronic obstructive pulmonary disease with chronic bronchitis using metered cryospray. The company's device incorporates software-driven dosimetry and specialty catheters, enabling the medical industry to facilitate precise delivery of cryogenic spray to freeze and destroy damaged airway cells, promoting healing and reducing symptoms such as mucus production, cough, and inflammation.
- Sector
- Healthcare
- HQ
- Lexington, MA, United States
- Founded
- 1993
- Employees
- 31
- Website
- rejuvenair.com/
- Ownership
- Privately Held (backing)
RejuvenAir doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in RejuvenAir shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on RejuvenAir in its N-PORT filings yet. We sweep new filings monthly.